Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report

Author： Kawasaki Kenta Hamamoto Yasuo Adachi Masayuki Kanai Takanori Takaishi Hiromasa

E-ISSN： 1792-1082|11|1|231-233

ISSN： 1792-1074

Source： Oncology Letters, Vol.11, Iss.1, 2016-01, pp. : 231-233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: A case report

Oncology Letters, Vol. 11, Iss. 1, 2016-01 ,pp. : 85-88

Spandidos Publications

Access to resources Recommend Favorite

How I Treat Metastatic Colorectal Cancer: Incorporating Regorafenib into Therapy

By Scheithauer Werner Ychou Marc

The Journal of OncoPathology, Vol. 2, Iss. 2, 2014-06 ,pp. : 11-18

Optimal Clinical Ltd

Access to resources Recommend Favorite

Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer

By Cremolini Chiara Schirripa Marta Loupakis Fotios Falcone Alfredo

Colorectal Cancer, Vol. 2, Iss. 5, 2013-10 ,pp. : 411-417

Future Medicine

Access to resources Recommend Favorite

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

The Oncologist, Vol. 23, Iss. 1, 2018-01 ,pp. : 7-15

John Wiley & Sons Inc

Access to resources Recommend Favorite

Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature

By Moroni Mauro

Targeted Oncology, Vol. 3, Iss. 2, 2008-04 ,pp. : 127-130

Springer Publishing Company

Access to resources Recommend Favorite